Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Atea Pharmaceuticals, Inc. clinical trials
The registry lists 33 studies whose lead sponsor is Atea Pharmaceuticals, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 31, 2026.
Keep track of what changes. Save the Atea Pharmaceuticals, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Atea Pharmaceuticals, Inc..
- Atea Pharmaceuticals, Inc.33 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 33 of 33.
- Study of AT-587 in Healthy SubjectsRecruitingNCT07728487Phase 1
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or MethadoneRecruitingNCT07314346Phase 1
- Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic FunctionCompletedNCT06911320Phase 1
- C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVActive, not recruitingNCT07037277Phase 3
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)CompletedNCT07272889Phase 1
- C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVActive, not recruitingNCT06868264Phase 3
- A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCVCompletedNCT05904470Phase 2
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and RosuvastatinCompletedNCT06921941Phase 1
- Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/RuzasvirCompletedNCT07007806Phase 1
- SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19CompletedNCT05629962Phase 3
- Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and RuzasvirCompletedNCT06204679Phase 1
- Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/RuzasvirCompletedNCT06356194Phase 1
- Study of AT-527 in Subjects With Normal and Impaired Renal FunctionCompletedNCT05618314Phase 1
- Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic FunctionCompletedNCT05724693Phase 1
- Study of AT-752 in Patients With Dengue InfectionTerminatedNCT05466240Phase 2
- Study of Bemnifosbuvir on Cardiac Repolarization in Healthy SubjectsCompletedNCT05905484Phase 1
- The Study of Bemnifosbuvir in Healthy Japanese SubjectsCompletedNCT05905497Phase 1
- Drug-drug Interaction Study of Ruzasvir and BemnifosbuvirCompletedNCT05731843Phase 1
- Study of AT-752 in Healthy Subjects in a Dengue Human Challenge ModelTerminatedNCT05366439Phase 1
- Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital SettingTerminatedNCT04396106Phase 2
- Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a MealCompletedNCT05256732Phase 1
- Study of AT-752 in Healthy SubjectsCompletedNCT04722627Phase 1
- Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected SubjectsWithdrawnNCT04309734Phase 1/2
- Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)CompletedNCT05137626Phase 1
- Bronchopulmonary PK of AT-527 (R07496998)CompletedNCT04877769Phase 1
- Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)CompletedNCT05154123Phase 1
- Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)CompletedNCT05004415Phase 1
- Study of AT-527 in Healthy Subjects (R07496998)CompletedNCT04711187Phase 1
- Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)CompletedNCT04849299Phase 1
- Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527CompletedNCT04784000Phase 1
- Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)CompletedNCT04865445Phase 1
- Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) InfectionCompletedNCT04019717Phase 2
- Study of AT-527 in Healthy and HCV-Infected SubjectsCompletedNCT03219957Phase 1